Rivoceranib
- Generic Name
- Rivoceranib
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
Albumin-Bound Paclitaxel Combined with Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
- Conditions
- Triple-negative Breast Cancer
- Interventions
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- The First Affiliated Hospital of Bengbu Medical University
- Target Recruit Count
- 128
- Registration Number
- NCT05192798
- Locations
- 🇨🇳
Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 35
- Registration Number
- NCT05171309
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
- Conditions
- Recurrent Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Target Recruit Count
- 178
- Registration Number
- NCT05156970
- Locations
- 🇨🇳
the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas
- Conditions
- Advanced or Metastatic EP-NEC
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 30
- Registration Number
- NCT05142865
- Locations
- 🇨🇳
Tongji Hospital，Tongji Medical College Affiliated，Huazhong University of Science ＆ Technology, Wuhan, Hubei, China
Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 102
- Registration Number
- NCT05095636
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
- Conditions
- Neoadjvant TherapyAnti-PD-1Oral Squamous Cell CarcinomaAnti-VEGFR
- Interventions
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 46
- Registration Number
- NCT05069857
- Locations
- 🇨🇳
Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Feng Wang
- Target Recruit Count
- 234
- Registration Number
- NCT05049681
Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 60
- Registration Number
- NCT05029453
- Locations
- 🇨🇳
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
- Conditions
- Advanced Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05019690
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
- Conditions
- Advanced Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT04985136
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.